– Highly efficient cell culture technology by adjusting the cell size and culture environment
– “SMUP-Cell” technology demonstrates the superiority of the next generation stem cell culture technology

MEDIPOST announced on October 24 that it has acquired a US patent on mesenchymal stem cell culturing methods based on the cell size. The patent is entitled, the ‘Method for Culturing Mesenchymal Stem Cells According to the Cell Size’, which is the technology for the method of culturing mesenchymal stem cells with high efficiency by controlling the stem cell size and culture environment.

MEDIPOST is expecting to apply this patent with the new process of mesenchymal stem cell production, enabling the mass production of cells with good stem cell functions such as proliferation and differentiation. Additionally, MEDIPOST has already obtained the patents of similar technologies in Korea, Japan, Australia and Europe, and the next-generation stem cells to which the patented technology is applied are called the ‘SMUP-Cell‘ and are currently in trial production.

A MEDIPOST representative commented that “this patent has already proven to have an international advantage in the technology of next-generation stem cell culture,” and that “pre-clinical studies are currently evaluating the efficacy and safety of new therapeutics using this technology.” Meanwhile, since 2012, the patent has been supported by the Ministry of Health and Welfare for the past five years in addition to receiving support from the stem cell regenerative medical consortium project.